CBL0137

Catalog No.S0507 Batch:S050702

Print

Technical Data

Formula

C21H24N2O2

Molecular Weight 336.43 CAS No. 1197996-80-7
Solubility (25°C)* In vitro DMSO 17 mg/mL (50.53 mM)
Ethanol 8 mg/mL (23.77 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5% DMSO 95% Corn oil
0.85mg/ml Taking the 1 mL working solution as an example, add 50 μL of 17 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
0.85mg/ml Taking the 1 mL working solution as an example, add 50 μL of 17 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description CBL0137 (Curaxin-137) is an inhibitor of the histone chaperone FACT (facilitates chromatin transcription) that simultaneously suppresses NF-κB and activates p53 with EC50 of 0.47 μM and 0.37 μM, respectively.
Targets
FACT [1] p53 [1]
(Cell-free assay)
NF-κB [1]
(Cell-free assay)
0.37 μM(EC50) 0.47 μM(EC50)

Protocol (from reference)

Selleck's CBL0137 has been cited by 7 publications

SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis [ JCI Insight, 2023, 8(4)e154120] PubMed: 36810256
CBL0137 activates ROS/BAX signaling to promote caspase-3/GSDME-dependent pyroptosis in ovarian cancer cells [ Biomed Pharmacother, 2023, 161:114529] PubMed: 37002567
SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes [ Nat Cancer, 2022, 3(2):188-202] PubMed: 35115713
Histone chaperone FACT complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of medulloblastoma to chemotherapy and radiation [ Cancer Lett, 2021, 520:201-212] PubMed: 34271103
The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma [ Cancer Lett, 2021, 499:232-242] PubMed: 33253788
HeLa TI cell-based assay as a new approach to screen for chemicals able to reactivate the expression of epigenetically silenced genes [ PLoS One, 2021, 16(6):e0252504] PubMed: 34115770
Chromatin Trapping of Factors Involved in DNA Replication and Repair Underlies Heat-Induced Radio- and Chemosensitization [ Cells, 2020, 9(6):1423] PubMed: 32521766

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.